Cypress Bioscience, Inc.
http://www.cypressbio.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cypress Bioscience, Inc.
Biopharma COVID-19 Collaborations May Avoid Antitrust Hurdles, FTC And DOJ Suggest
FTC and DoJ issue guidance for businesses working together to tackle coronavirus pandemic; BIO is 'pleased' they intend to help facilitate critical partnerships.
Coronavirus Update: R&D Starts, Product Delays, Continuing Collaboration
In addition to our daily in-depth coverage of key events relating to the coronavirus pandemic, we’re bringing you a periodic round-up of other significant developments.
Coronavirus Update: More Companies Join Therapeutics Accelerator, FDA Delays AdCom For First NASH Drug
As the global number of COVID-19 cases exceeds 500,000 for the first time, more biopharma companies throw their weight behind Gates Foundation's drug-hunting initiative.
Roche Launches COVID-19 Test For Cobas System; BioMérieux Plans Three COVID-19 Tests
Roche announced that the US FDA has granted an Emergency Use Authorization for the cobas SARS-CoV-2 test for patients suspected to have COVID-19. bioMérieux is planning three COVID-19 tests.
Company Information
- Industry
- Medical Devices
- Pharmaceuticals
- Services
-
In Vitro Diagnostics
- Therapeutic Drug Monitoring
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
- Other Names / Subsidiaries
-
- Cellatope Corporation
- Proprius Pharmaceuticals, Inc., Ramius LLC
- Royalty Pharma